A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage–Activated cGAS

A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage–Activated cGAS–STING Pathway

Published:2024-03-27 Issue:4 Volume:37 Page:561-570
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Jin Yonglong¹²,Wang Lijie¹,Jin Chengxue³⁴,Zhang Na¹,Shimizu Shosei⁵⁶,Xiao Wenjing¹,Guo Chuanlong⁷^ORCID,Liu Xiguang¹,Si Hongzong²

Affiliation:

1. Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266000, China

2. School of Public Health, Qingdao University, Qingdao 266071, China

3. Department of Molecular Craniofacial Embryology and Oral Histology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo 113-8510, Japan

4. Department of Oral, Plastic and Aesthetic Surgery, Hospital of Stomatology, Jilin University, Changchun, Jilin 130021, China

5. Department of Radiotherapy, Yizhou Tumor Hospital, Zhuozhou 072750, China

6. Department of Radiotherapy, University of Tsukuba Hospital, Tsukuba 305-8576, Japan

7. Department of Pharmacy, Qingdao University of Science and Technology, Qingdao 266041, China

Funder

China Scholarship Council

Qilu Special Project of Clinical Research Fund of Shandong Medical Association

Shandong traditional Chinese medicine science and technology development plan project

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.3c00343

Reference50 articles.

1. Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0

2. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012

3. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease

4. Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer